PANCREX V is a brand name for Amylase. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Pancrex V is used to compensate for reduced intestinal enzyme activity in pancreatic deficiency states. It is indicated for the treatment of fibrocystic disease of the pancreas (cystic fibrosis), chronic pancreatitis and pancreatic steatorrhoea following pancreatectomy. It may also be indicated following gastrectomy…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Dosage should be adjusted according to the needs of the individual patient and the amount and type of food consumed. The following dosage ranges provide a suitable basis for adjustment. Infants: the contents of 1 - 2 capsules mixed with feeds.
Older Children and Adults: the contents of 2 - 6 capsules with each snack or meal. The capsules may be swallowed. The capsules may provide a suitable alternative to the enteric coated presentations in cases where the pH of the duodenum is not sufficiently alkaline to dissolve the enteric coat.
Paediatric population Capsules provide a simple and convenient method of dose measurement of pancreatin for administration to younger children requiring a low dose. Method of administration Oral use. The capsules should be taken with each feed or meal or snack.
If the capsule contents are mixed with liquids or feeds the resulting mixture should not be allowed to stand for more than one hour prior to use.
Rare cases of hyperuricosuria and hyperuricaemia have been reported when extremely high doses of pancreatin have been taken. Strictures of the ileo-caecum and large bowel, and colitis, have been reported in children with cystic fibrosis taking high doses of pancreatic enzyme supplements.
To date Pancrex and Pancrex V presentations have not been implicated in the development of colonic damage. However, unusual abdominal symptoms or changes in abdominal symptoms should be reviewed to exclude the possibility of colonic damage especially if the patient is taking in excess of 10,000 units/kg/day of lipase.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
It is possible that some irritation of the skin of the mouth may occur if capsules are chewed or the contents retained in the mouth. Irritation of the anus may also occur. A barrier cream may prevent this local irritation. Allergic/asthmatic reactions have occasionally occurred on handling the capsule contents.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Amylase in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.